Mint Tower Capital Management’s Aimmune Therapeutics AIMT Stock Holding History

Mint Tower Capital Management’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-12,500	Closed	-$431K	–	419
2020 Q3	$431K	Buy	+12,500	New	+$266K	0.05%	161

Mint Tower Capital Management's AIMT Position: Q4 2020 in Review

Mint Tower Capital Management sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 12,500 shares — an estimated $431K sold.

Mint Tower Capital Management first reported a position in AIMT in Q3 2020 and held it in 1 quarter. The position peaked at $431K in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Mint Tower Capital Management reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Mint Tower Capital Management sold 12,500 Aimmune Therapeutics shares in Q4 2020, an estimated $431K.
Mint Tower Capital Management first reported a position in Aimmune Therapeutics in Q3 2020 and held it in 1 quarter.
Mint Tower Capital Management's Aimmune Therapeutics position peaked at $431K in Q3 2020.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Mint Tower Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.